LifeSci Advisors, LLC’s Post

🗣  A huge shoutout to the team at Lexicon Pharmaceuticals, Inc. as they seek to improve the quality of life for patients fighting through a common side effect of diabetes - pain from nerve damage. ❓ Did you know that as many as 50% of patients with diabetes suffer nerve damage related to the disease? This condition - known as diabetic neuropathy - can mean 2 extreme realities: 😖  Increased pain in their feet, legs and hands that make navigating life more difficult. ❗  Less feeling makes it more likely that minor injuries in those extremities turn into severe infections with dire long-term results - including amputation. 🤞🏿  Lexicon’s PROGRESS study (currently in Phase 2b) is the next step as the team seeks approval for a new, non-opioid drug to treat this pain. Its approval would be the first of its kind in more than 2 decades! 👏🏿  This is the type of project that fulfills the Medidata mission to “power smarter treatments and healthier people.” We’re thankful to partner with the team at Lexicon to PROGRESS this effort (pun absolutely intended)! #customerappreciation #DCT #EDC #decentralizedclinicaltrials #medidata #diabetes #patientadvocacy #patientcloud #clinicaltrials #diabeticperipheralneuropathy #electronicdatacapture #patientcloud Medidata Solutions Dassault Systèmes Phyllisa Deroze, PhD Alicia C. Staley Karen J. Wood Anthony Costello Meg Domanico Hood Steve Silverberg Matt Noble Lonnel Coats

MHN is exhibiting at next week's World of Pharmaceutical Market Research conference. Stop by our booth to meet Susan Owens and Andrew Hayes to learn about gaining access to MHN's proprietary panels featuring PATIENTS, PHYSICIANS, and HOSPITAL EXECUTIVES. #mrx #healthcareresearch #qualitativeresearch #MHN #aitransformation #quanitativeresearch #insights #marketingideas #howtoqualitative #PMRC #Quirks

MHN is exhibiting at next week's World of Pharmaceutical Market Research conference. Stop by our booth to meet Susan Owens and Andrew Hayes to learn about gaining access to MHN's proprietary panels featuring PATIENTS, PHYSICIANS, and HOSPITAL EXECUTIVES. #mrx #healthcareresearch #qualitativeresearch #MHN #aitransformation #quanitativeresearch #insights #marketingideas #howtoqualitative #PMRC #Quirks

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) CEO Brian Strem joined Steve Darling from Proactive to share news the company's plan to broaden the clinical development of KIO-301, a treatment designed for various inherited retinal diseases. The expansion includes initiating a Phase 2 trial which will be controlled, double-masked, randomized, and will involve an ascending-dose. This trial is set to include up to 20 patients suffering from Retinitis Pigmentosa (RP), who will receive doses monthly over a span of 90 days. Strem explained that this move is propelled by encouraging topline results from a Phase I/II clinical trial, which indicated that KIO-301 is a first-in-class small molecule with significant potential to improve vision for patients with RP, even those with extremely low vision or complete blindness. Moreover, Kiora Pharmaceuticals has plans to engage with the FDA in the fourth quarter of 2023. Watch at #Proactive #ProactiveInvestors #NASDAQ #KPRX http://ow.ly/2e8m1052gy1

Delighted to announce the publication of a pre-print by the esteemed HESI Cardiac Safety Committee (https://lnkd.in/gMDu5VY) describing a new Cardiac Compound Tool Database! This new database (https://lnkd.in/gKYRrX3z) contains information on 128 pharmaceutical agents, including their cardiotoxic properties. Curated by subject matter experts and sourced from reputable literature and online databases, this resource provides details such as compound name, mode of action, cardiac toxicity profile, and more. The user-friendly interface allows for easy access and submission of new data, ensuring the database remains up-to-date and valuable for safety assessment and research on drug-induced cardiac toxicity. Read the full pre-print here: https://lnkd.in/gjR8dpAu

MHN is exhibiting at next week's World of Pharmaceutical Market Research conference. Stop by our booth to meet Susan Owens and Andrew Hayes to learn about gaining access to MHN's proprietary panels featuring PATIENTS, PHYSICIANS, and HOSPITAL EXECUTIVES. #mrx #healthcareresearch #qualitativeresearch #MHN #aitransformation #quanitativeresearch #insights #marketingideas #howtoqualitative #PMRC #Quirks

MHN is exhibiting at next week's World of Pharmaceutical Market Research conference. Stop by our booth to meet Susan Owens and Andrew Hayes to learn about gaining access to MHN's proprietary panels featuring PATIENTS, PHYSICIANS, and HOSPITAL EXECUTIVES. #mrx #healthcareresearch #qualitativeresearch #MHN #aitransformation #quanitativeresearch #insights #marketingideas #howtoqualitative #PMRC #Quirks

MHN is exhibiting at next week's World of Pharmaceutical Market Research conference. Stop by our booth to meet Susan Owens and Andrew Hayes and learn about our proprietary panels, featuring PATIENTS, PHYSICIANS and HOSPITAL EXECUTIVES. #mrx #healthcareresearch #qualitativeresearch #MHN #aitransformation #quanitativeresearch #insights #marketingideas #howtoqualitative #PMRC #Quirks

...proud, as this research started more than 10 years ago at KU Leuven when we were looking for compounds that can increase the activity of antifungal drugs. In this way, we identified the very potent and fungicidal miconazole - domiphen bromide combination, which now proved to be more effective in patients than standard-of-care. …with support of Industrial Research Fund (IOF) and VLAIO #translationalresearch

Cough in Idiopathic Pulmonary Fibrosis Market Size in the 7MM is estimated to Increase by 2032 | Nerre Therapeutics Ltd., Pharm-Olam International, Trevi Therapeutics, Parexel, Afferent Pharmaceuticals Inc., and others. https://lnkd.in/eHZUnUyu #marketanalysis #marketresearch #marketresearchreports #businessintelligence